Physician profile
Heather S Volpp
NPI 1083702120
$993.73
in general payments reported to CMS, 2019-2025
15 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $189 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $181.10 | 2019-2020 | |
| Shire North American Group INC | $147.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $130.41 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $115.42 | 2019-2020 | |
| Genzyme Corporation | $93.45 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $68.59 | 2019-2020 | |
| Pfizer INC. | $61.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.81 | 2019 | |
| Kaleo, INC. | $33.67 | 2019 | |
| Optinose US, INC. | $23.93 | 2019 | |
| Alk-Abello, INC | $23.32 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.72 | 2020 | |
| Genentech USA, INC. | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Volpp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.